ROIV:NASDAQ
Roivant Sciences Ltd
$39.20
arrow_downward
-1.43%(-0.57) 1D
Sep 21, 2:30:49 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$39.02
High
$39.90
Low
$38.72
Mkt. cap
28.30B
Avg. vol.
8.95M
Volume
2.93M
52-wk high
$42.50
52-wk low
$14.50
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
Open
$39.02
High
$39.90
Low
$38.72
Mkt. cap
28.30B
Avg. vol.
8.95M
Volume
2.93M
52-wk high
$42.50
52-wk low
$14.50
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
News stories
From web sources and news partners
International Business Times UK
·
6 hours ago
Vivek Ramaswamy Sold an Estimated $1.2B in Stock, Now Could Become the Third-Richest US Elected Official
Simply Wall Street
·
2 days ago
Did Positive PH ILD Trial Data Just Shift Roivant Stock Investment Narrative?
Stock Titan
·
2 days ago
Roivant Sciences (ROIV) director now holds 8.97M shares
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd